Isla M. Ogilvie, PhD, Nick Newton, PhD, Sharon A

Slides:

Advertisements

Similar presentations

An Unusual Electrocardiogram in a Heart Transplant Recipient Hamish I. MacLachlan, BSc, MBBS, Jonathan R. Dalzell, MD, MRCP The American Journal of Medicine.

Advertisements

CHA2DS2-VASC and CHADS2 Scores Predict Adverse Clinical Events in Patients With Pacemakers and Sinus Node Dysfunction Independent of Atrial Fibrillation

Long-Term Population-Based Cerebral Ischemic Event and Cognitive Outcomes of Direct Oral Anticoagulants Compared With Warfarin Among Long-term Anticoagulated.

Paul D. Stein, MD, Fadi Matta, MD, Mary J. Hughes, DO

New-onset Atrial Fibrillation Predicts Heart Failure Progression

Bleeding Toes in Diabetic Neuropathy

Role of the CHADS2 Score in Acute Coronary Syndromes

Renato D. Lopes, MD, PhD, Li Li, MS, Christopher B

CHADS2 Score Predicts Postoperative Atrial Fibrillation in Patients Undergoing Elective Pulmonary Lobectomy Svetlana Kotova, MD, Mansen Wang, PhD, Katie.

Dabigatran and Warfarin for Secondary Prevention of Stroke in Atrial Fibrillation Patients: A Nationwide Cohort Study Torben Bjerregaard Larsen, MD,

Focused 2012 Update of the Canadian Cardiovascular Society Atrial Fibrillation Guidelines: Recommendations for Stroke Prevention and Rate/Rhythm Control

An Unusual Cause of Leg Ulcerations

Antithrombotic Treatment Patterns in Patients with Newly Diagnosed Nonvalvular Atrial Fibrillation: The GLORIA-AF Registry, Phase II Menno V. Huisman,

Volume 137, Issue 2, Pages (February 2010)

Dabigatran and Warfarin for Secondary Prevention of Stroke in Atrial Fibrillation Patients: A Nationwide Cohort Study Torben Bjerregaard Larsen, MD,

Richard V. Milani, MD, Carl J. Lavie, MD, Robert M

Bleeding Toes in Diabetic Neuropathy

Trends in Comorbidity, Disability, and Polypharmacy in Heart Failure

Systematic Review of the Mediterranean Diet for Long-Term Weight Loss

Leslie R. Harrold, MD, MPH, Daniel Peterson, MS, Ashley J

CHA2DS2-VASc Score Is Directly Associated with the Risk of Pulmonary Embolism in Patients with Atrial Fibrillation Walid Saliba, MD, MPH, Gad Rennert,

Trends in Stroke Rates, Risk, and Outcomes in the United States, 1988 to 2008 Margaret C. Fang, MD, MPH, Marcelo Coca Perraillon, MA, Kaushik Ghosh, PhD,

Net Clinical Benefit of Non-vitamin K Antagonist Oral Anticoagulants Versus Warfarin in Phase III Atrial Fibrillation Trials Giulia Renda, MD, PhD, Marta.

SAMe-TT2R2 Score, Time in Therapeutic Range, and Outcomes in Anticoagulated Patients with Atrial Fibrillation Pilar Gallego, MD, PhD, Vanessa Roldán,

Effect of Aspirin on Mortality in the Primary Prevention of Cardiovascular Disease Nina Raju, MD, MsC, Magdalena Sobieraj-Teague, MBBS, Jack Hirsh, MD,

‘Real-World’ Antithrombotic Treatment in Atrial Fibrillation: The EORP-AF Pilot Survey Gregory Y.H. Lip, MD, Cécile Laroche, MSc, Gheorghe-Andrei Dan,

Thomas E. MacMillan, MD, MSc, Terence Tang, MD, Rodrigo B

Epidemiology of Myelodysplastic Syndromes

Trend in Mortality after Stroke with Atrial Fibrillation

The Impact of Race on the Prognosis of Preclinical Diastolic Dysfunction: A Large Multiracial Urban Population Study Jian Shan, MD, Lili Zhang, MD, MSc,

Antibiotic Therapy and 48-Hour Mortality for Patients with Pneumonia

Robert Goulden, MBBS, MSc, MPhil, MA The American Journal of Medicine

Gregory Y.H. Lip, MD, Jonathan L. Halperin, MD, Hung-Fat Tse, MD, PhD

Methylene Chloride Intoxication Treated With Hyperbaric Oxygen Therapy

Triple vs Dual Antithrombotic Therapy in Patients with Atrial Fibrillation and Coronary Artery Disease Renato D. Lopes, MD, MHS, PhD, Meena Rao, MD,

CHADS2 Score, Statin Therapy, and Risks of Atrial Fibrillation

The Reply The American Journal of Medicine

TIA for the Internist The American Journal of Medicine

Hong-Tao Tie, MD, Rui Shi, MD The American Journal of Medicine

History of Thyroid Disorders in Relation to Clinical Outcomes in Atrial Fibrillation Helene Bruere, MD, Laurent Fauchier, MD, PhD, Anne Bernard Brunet,

Are Atrial Fibrillation Patients Receiving Warfarin in Accordance with Stroke Risk? Peter J. Zimetbaum, MD, Amit Thosani, MD, Hsing-Ting Yu, MPH, Yan.

Truman J. Milling, MD, Alex C. Spyropoulos, MD

Evaluation of the HAS-BLED, ATRIA, and ORBIT Bleeding Risk Scores in Patients with Atrial Fibrillation Taking Warfarin Keitaro Senoo, MD, Marco Proietti,

When Guidelines Cause Hypertension

The Impact of Prior Heart Failure Hospitalizations on Long-term Mortality Differs by Baseline Risk of Death Naga V.A. Kommuri, MD, Todd M. Koelling,

Left atrial appendage exclusion: An alternative to anticoagulation in nonvalvular atrial fibrillation Kareem Bedeir, MBChB, MS, David R. Holmes, MD,

Optimizing Atrial Fibrillation Management

The Malnourished Heart: An Unusual Case of Heart Failure

External Validation of the Simple NULL-PLEASE Clinical Score in Predicting Outcome of Out-of-Hospital Cardiac Arrest Tatjana S. Potpara, MD, PhD, Miroslav.

The Reply The American Journal of Medicine

Usefulness of CHADS2 and CHA2DS2-VASc Scores in the Prediction of New-Onset Atrial Fibrillation: A Population-Based Study Walid Saliba, MD, MPH, Naomi.

Independent of Cirrhosis, Hepatocellular Carcinoma Risk Is Increased with Diabetes and Metabolic Syndrome Allison J. Kasmari, MD, Amy Welch, MD, MSN,

Age Differences in Treatment and Control of Hypertension in US Physician Offices, : A Serial Cross-sectional Study Anna Gu, MD, PhD, Yu Yue,

Eroded Pacemaker in an Elderly Patient

To Reduce Stroke with PFO Closure, Respect the Shunt

Sophia C. Kamran, William F. Pendergraft, MD, David C

Stroke and Bleeding Risk Co-distribution in Real-world Patients with Atrial Fibrillation: The Euro Heart Survey Maura Marcucci, MD, Gregory Y.H. Lip,

Yoko Miyasaka, MD, PhD, Marion E. Barnes, MSc, Bernard J

National Trends in Ambulatory Oral Anticoagulant Use

A Post-cure Complication

Risk of Falls and Major Bleeds in Patients on Oral Anticoagulation Therapy Jacques Donzé, MD, MSc, Carole Clair, MSc, MD, Balthasar Hug, MD, MBA, MPH,

Combining Antiplatelet and Antithrombotic Therapy (Triple Therapy): What Are the Risks and Benefits? Luis Alejandro Asencio, MD, Jennifer J. Huang, DO,

Erratum Canadian Journal of Cardiology

Rebecca D. Chason, Joan S. Reisch, PhD, Don C. Rockey, MD

Falls in Older Adults: Risk Assessment, Management and Prevention

Figure 8. Stroke prevention strategy in patients with AF

Has mortality from acute renal failure decreased

Toward a More Responsible News Media

Preoperative Thienopyridine Use and Outcomes after Surgery: A Systematic Review Anita G. Au, MD, Sumit R. Majumdar, MD MPH, Finlay A. McAlister, MD MSc

Hypophosphatemia: Diagnostic Significance in Legionnaires’ Disease

Presentation transcript:

Underuse of Oral Anticoagulants in Atrial Fibrillation: A Systematic Review Isla M. Ogilvie, PhD, Nick Newton, PhD, Sharon A. Welner, PhD, Warren Cowell, MSc, Gregory Y.H. Lip, MD The American Journal of Medicine Volume 123, Issue 7, Pages 638-645.e4 (July 2010) DOI: 10.1016/j.amjmed.2009.11.025 Copyright © 2010 Elsevier Inc. Terms and Conditions

Figure 1 Literature search and study inclusion for oral anticoagulation treatment levels. CHADS2=congestive heart failure, hypertension, age >75 years, diabetes mellitus, and prior stroke or transient ischemic attack. The American Journal of Medicine 2010 123, 638-645.e4DOI: (10.1016/j.amjmed.2009.11.025) Copyright © 2010 Elsevier Inc. Terms and Conditions

Figure 2 Patients with atrial fibrillation and prior stroke/transient ischemic attack: oral anticoagulation treatment levels as a proportion of patients eligible for oral anticoagulation therapy. *Contraindications taken into account. The American Journal of Medicine 2010 123, 638-645.e4DOI: (10.1016/j.amjmed.2009.11.025) Copyright © 2010 Elsevier Inc. Terms and Conditions

Figure 3 Patients with atrial fibrillation at high risk of stroke (CHADS2 score): oral anticoagulant treatment levels as a proportion of patients eligible for therapy. *Includes patients treated with both oral anticoagulation therapy and antiplatelet therapy. †Patients defined as having a CHADS2 score of >1 and a bleeding score of <2 (the n value for this population was not available). CHADS2=congestive heart failure, hypertension, age >75 years, diabetes mellitus, and prior stroke or transient ischemic attack. The American Journal of Medicine 2010 123, 638-645.e4DOI: (10.1016/j.amjmed.2009.11.025) Copyright © 2010 Elsevier Inc. Terms and Conditions